Emergent BioSolutions exercises $20M option to supply DoD with BioThrax

Emergent BioSolutions (EBS) announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax to the U.S. Department of Defense, DoD. The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025. “We’re pleased to continue our work with the U.S. Department of Defense to supply BioThrax to protect our nation’s service members who have a high risk of exposure to anthrax,” said Paul Williams, senior vice president, products head at Emergent. “This procurement ensures a continued supply of this important medical countermeasure to the U.S. military and demonstrates our commitment to delivering solutions that address our customers’ needs to prepare for public health threats.”